Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study
Publication
, Conference
Chari, A; Chhabra, S; Usmani, S; Larson, S; Niesvizky, R; Matous, J; Gasparetto, C; Holkova, B; Lunning, M; Valent, J; Anderson, LD; Kwei, L ...
Published in: BLOOD
December 3, 2015
Duke Scholars
Published In
BLOOD
EISSN
1528-0020
ISSN
0006-4971
Publication Date
December 3, 2015
Volume
126
Issue
23
Location
Orlando, FL
Publisher
AMER SOC HEMATOLOGY
Conference Name
57th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Chari, A., Chhabra, S., Usmani, S., Larson, S., Niesvizky, R., Matous, J., … McDonagh, K. (2015). Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study. In BLOOD (Vol. 126). Orlando, FL: AMER SOC HEMATOLOGY.
Chari, Ajai, Saurabh Chhabra, Saad Usmani, Sarah Larson, Ruben Niesvizky, Jeffrey Matous, Cristina Gasparetto, et al. “Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study.” In BLOOD, Vol. 126. AMER SOC HEMATOLOGY, 2015.
Chari A, Chhabra S, Usmani S, Larson S, Niesvizky R, Matous J, et al. Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study. In: BLOOD. AMER SOC HEMATOLOGY; 2015.
Chari, Ajai, et al. “Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study.” BLOOD, vol. 126, no. 23, AMER SOC HEMATOLOGY, 2015.
Chari A, Chhabra S, Usmani S, Larson S, Niesvizky R, Matous J, Gasparetto C, Holkova B, Lunning M, Valent J, Anderson LD, Karanes C, Kwei L, Chang L, Graef T, Bilotti E, McDonagh K. Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study. BLOOD. AMER SOC HEMATOLOGY; 2015.
Published In
BLOOD
EISSN
1528-0020
ISSN
0006-4971
Publication Date
December 3, 2015
Volume
126
Issue
23
Location
Orlando, FL
Publisher
AMER SOC HEMATOLOGY
Conference Name
57th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology